Asfotase alfa

Asfotase alfa is a prescription medication used to treat hypophosphatasia, a genetic disorder that affects the bones and teeth. It works by helping the body to break down and use phosphorus, which is important for building and maintaining strong bones. Asfotase alfa is given as an injection into the muscle or under the skin. Common side effects may include pain, redness, or swelling at the injection site, headache, fever, and nausea.

Asfotase alfa, sold under the brand name Strensiq, is a medication used to treat a rare genetic disorder called hypophosphatasia (HPP). Here's a breakdown of its key aspects:

Function:

• Enzyme replacement therapy: Asfotase alfa is a recombinant form of the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme, which is deficient in individuals with HPP. This enzyme plays a crucial role in bone mineralization by helping the body process calcium and phosphorus.
• Improves bone mineralization: By replacing the missing enzyme, Asfotase alfa helps to improve bone mineralization, leading to stronger and healthier bones.

Uses:

• Treats HPP: Asfotase alfa is specifically indicated for treating the following types of HPP:
  • Perinatal/infantile-onset HPP: Affects newborns and infants, causing severe skeletal deformities and respiratory problems.
  • Juvenile-onset HPP: Develops in early childhood, leading to bone pain, fractures, and growth problems.

Administration:

• Subcutaneous injection: Asfotase alfa is administered by subcutaneous injection (under the skin) typically in the abdomen, thighs, or buttocks by a healthcare professional.
• Dosing: The specific dosage and frequency of injections are determined by the doctor based on the severity of the individual's HPP and their response to treatment.

Mechanism of Action:

• Replaces deficient enzyme: Asfotase alfa acts by directly replacing the missing TNSALP enzyme in the body.
• Improves mineral absorption: The enzyme helps to break down specific molecules in the blood, allowing for better absorption of calcium and phosphorus from the intestines and facilitating their incorporation into bones, thereby promoting bone mineralization.

Benefits:

• Improves bone health: Asfotase alfa treatment can significantly improve bone mineralization, leading to:
  • Reduced bone pain and fractures
  • Improved mobility and function
  • Reduced respiratory problems in infants
• First-in-class treatment: Asfotase alfa is the first and only FDA-approved treatment specifically for HPP.

Considerations:

• Lifelong treatment: HPP is a chronic condition, and Asfotase alfa is typically needed for long-term treatment.
• Potential side effects: As with any medication, Asfotase alfa can cause side effects, although not everyone experiences them. Common side effects include injection site reactions, hypersensitivity reactions, and lipodystrophy (changes in fat distribution at the injection site).
• Monitoring: Regular monitoring by a healthcare professional is essential during treatment to assess progress and manage potential side effects.